At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Patidegib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
In Brief
A Phase 2 clinical trial evaluating Patidegib and Vehicle gel for Basal Cell Nevus Syndrome. Completed, enrolled 17 participants across 2 sites.
Detailed Summary
Multicenter, double-blind, randomized, vehicle-controlled study that evaluates the efficacy and safety of patidegib gel 2% and 4% in comparison with vehicle in participants at least 18 years of age that meet the diagnostic criteria for basal cell nevus syndrome (BCNS). Participants will be randomized to receive patidegib gel 2%, patidegib gel 4%, or the vehicle gel for a 26-week treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBasal Cell Nevus Syndrome
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJun 2016
Primary CompletionApr 2017
TodayJul 2026
First PostedMay 4, 2016
Enrollment StartJun 6, 2016
Primary CompletionApr 24, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.2 years ago
Interventions
Patidegibdrug
Vehicle geldrug